scd23 r d systems Search Results


scd23 r d systems  (R&D Systems)
90
R&D Systems scd23 r d systems
Scd23 R D Systems, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/scd23 r d systems/product/R&D Systems
Average 90 stars, based on 1 article reviews
scd23 r d systems - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
soluble form cd23 (scd23  (R&D Systems)
90
R&D Systems soluble form cd23 (scd23
The expression of B-cell differentiation (CD5), maturation <t>(CD23)</t> and calcium signaling (CD38) cell markers was analyzed on B-cells (frequency and median fluorescence intensity, MFI) to characterize B-cell phenotype in circulation in early RA (ERA) and established RA patients under methotrexate treatment. The effect of TNF-inhibitors and tocilizumab treatment on B-cell markers expression was also assessed in established RA patients at baseline and after an average of 8 months of treatment. Bars represent median values with interquartile range. Differences were considered statistically significant for p <0.05. Non-parametric Mann-Whitney test was used for comparisons between 2 independent groups. For paired samples (before and after treatment), the Wilcoxon signed-rank test was used.
Soluble Form Cd23 (Scd23, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/soluble form cd23 (scd23/product/R&D Systems
Average 90 stars, based on 1 article reviews
soluble form cd23 (scd23 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
human quantikine® scd23  (R&D Systems)
90
R&D Systems human quantikine® scd23
Box (median with IQR) and whisker (10th and 90th percentiles), and before‐after plots of <t>sCD23</t> serum levels in the peripheral blood of healthy nonpregnant women and those with atopic asthma (HNP and ANP), during the third trimester of pregnancy (HP and AP), and during the postpartum period at least 6 weeks after delivery (HP/PP and AP/PP). Differences between unpaired and paired groups were tested using the Mann‐Whitney U ‐test or Wilcoxon signed‐rank test, respectively (A). Correlations between sCD23 serum levels and CD24 Hi CD27 + B‐cells (B), CD24 Hi CD38 Hi B‐cells (C) and IL‐10 secreting B‐cells (D) in ANP women. For (B), (C) and (D), Spearman correlation coefficients, 95% confidence intervals, and p ‐values are indicated. HNP: n = 35; HP: n = 43; HP/PP: n = 42; ANP: n = 32; AP: n = 20; AP/PP: n = 12. * p ‐value <0.05; ** p ‐value <0.01; *** p ‐value <0.001. Shaded areas represent normal range. All data regarding healthy women was adapted from Lima et al.
Human Quantikine® Scd23, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human quantikine® scd23/product/R&D Systems
Average 90 stars, based on 1 article reviews
human quantikine® scd23 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


The expression of B-cell differentiation (CD5), maturation (CD23) and calcium signaling (CD38) cell markers was analyzed on B-cells (frequency and median fluorescence intensity, MFI) to characterize B-cell phenotype in circulation in early RA (ERA) and established RA patients under methotrexate treatment. The effect of TNF-inhibitors and tocilizumab treatment on B-cell markers expression was also assessed in established RA patients at baseline and after an average of 8 months of treatment. Bars represent median values with interquartile range. Differences were considered statistically significant for p <0.05. Non-parametric Mann-Whitney test was used for comparisons between 2 independent groups. For paired samples (before and after treatment), the Wilcoxon signed-rank test was used.

Journal: PLoS ONE

Article Title: B-cell phenotype and IgD-CD27- memory B cells are affected by TNF-inhibitors and tocilizumab treatment in rheumatoid arthritis

doi: 10.1371/journal.pone.0182927

Figure Lengend Snippet: The expression of B-cell differentiation (CD5), maturation (CD23) and calcium signaling (CD38) cell markers was analyzed on B-cells (frequency and median fluorescence intensity, MFI) to characterize B-cell phenotype in circulation in early RA (ERA) and established RA patients under methotrexate treatment. The effect of TNF-inhibitors and tocilizumab treatment on B-cell markers expression was also assessed in established RA patients at baseline and after an average of 8 months of treatment. Bars represent median values with interquartile range. Differences were considered statistically significant for p <0.05. Non-parametric Mann-Whitney test was used for comparisons between 2 independent groups. For paired samples (before and after treatment), the Wilcoxon signed-rank test was used.

Article Snippet: B cell activating factor (BAFF) (Bender MedSystems, Austria), B-lymphocyte chemoattractant (BLC) also known as C-X-C motif chemokine 13 (CXCL13) and the soluble form of CD23 (sCD23) (R&D systems, United Kingdom) were quantified in serum samples from all groups by ELISA according to the manufacturer’s instructions.

Techniques: Expressing, Cell Differentiation, Fluorescence, MANN-WHITNEY

The serum levels of C-X-C motif chemokine 13 (CXCL13) (A) , soluble CD23 (sCD23) (B) and B cell activating factor (BAFF) (C) were quantified in early RA (ERA) and established RA patients under methotrexate treatment by ELISA. The effect of TNF-inhibitors and tocilizumab treatment in the production of these serological markers was also assessed in established RA patients at baseline and after an average of 8 months of treatment. Lines represent median values. Differences were considered statistically significant for p <0.05. Non-parametric Mann-Whitney test was used for comparisons between 2 independent groups. For paired samples (before and after treatment), the Wilcoxon signed-rank test was used.

Journal: PLoS ONE

Article Title: B-cell phenotype and IgD-CD27- memory B cells are affected by TNF-inhibitors and tocilizumab treatment in rheumatoid arthritis

doi: 10.1371/journal.pone.0182927

Figure Lengend Snippet: The serum levels of C-X-C motif chemokine 13 (CXCL13) (A) , soluble CD23 (sCD23) (B) and B cell activating factor (BAFF) (C) were quantified in early RA (ERA) and established RA patients under methotrexate treatment by ELISA. The effect of TNF-inhibitors and tocilizumab treatment in the production of these serological markers was also assessed in established RA patients at baseline and after an average of 8 months of treatment. Lines represent median values. Differences were considered statistically significant for p <0.05. Non-parametric Mann-Whitney test was used for comparisons between 2 independent groups. For paired samples (before and after treatment), the Wilcoxon signed-rank test was used.

Article Snippet: B cell activating factor (BAFF) (Bender MedSystems, Austria), B-lymphocyte chemoattractant (BLC) also known as C-X-C motif chemokine 13 (CXCL13) and the soluble form of CD23 (sCD23) (R&D systems, United Kingdom) were quantified in serum samples from all groups by ELISA according to the manufacturer’s instructions.

Techniques: Enzyme-linked Immunosorbent Assay, MANN-WHITNEY

The expression of cell markers (CD5, CD23, CD38, CD69, CD86 and CD95) was analyzed on B-cells (frequency and median fluorescence intensity, MFI) by flow cytometry in established RA patients before and after an average of 8 months of biologic therapy with TNF-inhibitors and/ or tocilizumab, based on whether the patients presented a low to moderate disease activity (DAS28<3.2) or high disease activity (DAS28>3.2) after treatment. Differences were considered statistically significant for p <0.05 (Wilcoxon signed-rank test).

Journal: PLoS ONE

Article Title: B-cell phenotype and IgD-CD27- memory B cells are affected by TNF-inhibitors and tocilizumab treatment in rheumatoid arthritis

doi: 10.1371/journal.pone.0182927

Figure Lengend Snippet: The expression of cell markers (CD5, CD23, CD38, CD69, CD86 and CD95) was analyzed on B-cells (frequency and median fluorescence intensity, MFI) by flow cytometry in established RA patients before and after an average of 8 months of biologic therapy with TNF-inhibitors and/ or tocilizumab, based on whether the patients presented a low to moderate disease activity (DAS28<3.2) or high disease activity (DAS28>3.2) after treatment. Differences were considered statistically significant for p <0.05 (Wilcoxon signed-rank test).

Article Snippet: B cell activating factor (BAFF) (Bender MedSystems, Austria), B-lymphocyte chemoattractant (BLC) also known as C-X-C motif chemokine 13 (CXCL13) and the soluble form of CD23 (sCD23) (R&D systems, United Kingdom) were quantified in serum samples from all groups by ELISA according to the manufacturer’s instructions.

Techniques: Expressing, Fluorescence, Flow Cytometry, Activity Assay

Box (median with IQR) and whisker (10th and 90th percentiles), and before‐after plots of sCD23 serum levels in the peripheral blood of healthy nonpregnant women and those with atopic asthma (HNP and ANP), during the third trimester of pregnancy (HP and AP), and during the postpartum period at least 6 weeks after delivery (HP/PP and AP/PP). Differences between unpaired and paired groups were tested using the Mann‐Whitney U ‐test or Wilcoxon signed‐rank test, respectively (A). Correlations between sCD23 serum levels and CD24 Hi CD27 + B‐cells (B), CD24 Hi CD38 Hi B‐cells (C) and IL‐10 secreting B‐cells (D) in ANP women. For (B), (C) and (D), Spearman correlation coefficients, 95% confidence intervals, and p ‐values are indicated. HNP: n = 35; HP: n = 43; HP/PP: n = 42; ANP: n = 32; AP: n = 20; AP/PP: n = 12. * p ‐value <0.05; ** p ‐value <0.01; *** p ‐value <0.001. Shaded areas represent normal range. All data regarding healthy women was adapted from Lima et al.

Journal: American Journal of Reproductive Immunology

Article Title: Serum markers of B‐cell activation in pregnant women with atopic asthma

doi: 10.1111/aji.13414

Figure Lengend Snippet: Box (median with IQR) and whisker (10th and 90th percentiles), and before‐after plots of sCD23 serum levels in the peripheral blood of healthy nonpregnant women and those with atopic asthma (HNP and ANP), during the third trimester of pregnancy (HP and AP), and during the postpartum period at least 6 weeks after delivery (HP/PP and AP/PP). Differences between unpaired and paired groups were tested using the Mann‐Whitney U ‐test or Wilcoxon signed‐rank test, respectively (A). Correlations between sCD23 serum levels and CD24 Hi CD27 + B‐cells (B), CD24 Hi CD38 Hi B‐cells (C) and IL‐10 secreting B‐cells (D) in ANP women. For (B), (C) and (D), Spearman correlation coefficients, 95% confidence intervals, and p ‐values are indicated. HNP: n = 35; HP: n = 43; HP/PP: n = 42; ANP: n = 32; AP: n = 20; AP/PP: n = 12. * p ‐value <0.05; ** p ‐value <0.01; *** p ‐value <0.001. Shaded areas represent normal range. All data regarding healthy women was adapted from Lima et al.

Article Snippet: For sCD23 quantification, serum samples were analyzed with Human Quantikine® sCD23 (R&D Systems Europe Ltd).

Techniques: Whisker Assay, MANN-WHITNEY

Comparison of B‐cell activation markers in AP AMP and AP NAMP groups

Journal: American Journal of Reproductive Immunology

Article Title: Serum markers of B‐cell activation in pregnant women with atopic asthma

doi: 10.1111/aji.13414

Figure Lengend Snippet: Comparison of B‐cell activation markers in AP AMP and AP NAMP groups

Article Snippet: For sCD23 quantification, serum samples were analyzed with Human Quantikine® sCD23 (R&D Systems Europe Ltd).

Techniques: Comparison, Activation Assay